Marijuana Studies and

Cannabis Research

09/28/2018
Author(s): C Benito, RM Tolo´n, MR Pazos, E Nu´n˜ez, AI Castillo, and J Romero. The anti-inflammatory effects triggered by the activation of CB2 receptor make it an attractive target for the development of new anti-inflammatory therapies. In any case, more research is needed to corroborate the potential utility of cannabinoid-based treatments devoid of unwanted psychoactive effects. View study
09/28/2018
Author(s): . This study demonstrates that dimethylheptyl-cannabidiol (DMH-CBD) has anti-inflammatory and antiproliferative properties similar to cannabidiol (CBD). DMH-CBD acts by negatively regulating the expression of inflammatory cytokines and protecting microglial cells by inducing an adaptive cellular response against inflammatory stimuli and oxidative lesions. View study
09/28/2018
Author(s): A Alhamoruni1, KL Wright2, M Larvin1 and SE O’Sullivan1. Cannabinoids can modulate intestinal permeability in an in vitro model of inflammation. This study suggests that cannabis-based drugs may be of therapeutic benefit in the treatment of inflammatory bowel disorders associated with abnormal intestinal permeability. View study
09/28/2018
Author(s): Wei Xiong,1 Tanxing Cui,3,4,5 Kejun Cheng,2 Fei Yang,6 Shao-Rui Chen,7 Dan Willenbring,3,4,5 Yun Guan,6 Hui-Lin Pan,7 Ke Ren,8 Yan Xu,3,4,5 and Li Zhang1. Chronic pain produced by diseases that involve the dysfunction of glycine receptors (GlyR) can be alleviated and treated by cannabinoids, which are evidenced as therapeutic agents. View study
09/28/2018
Author(s): M. Mecha, A. Feliú, P.M. Iñigo, L. Mestre, F.J. Carrillo-Salinas, C. Guaza. This study results highlight the anti-inflammatory effects of cannabidiol in this viral model of multiple sclerosis and demonstrate the significant therapeutic potential of this compound for the treatment of pathologies with an inflammatory component. View study
09/28/2018
Author(s): Kun Li, Jia-yan Feng, Yong-yu Li, Birol Yuece, Xu-hong Lin, Liang-ying Yu, Yan-na Li,Ya-jing Feng, and Martin Storr. The treatment with cannabidiol or O-1602 significantly improved the pathological changes of mice with experimental acute pancreatitis, showing anti-inflammatory effects. View study Inflammation in the CNS (1)inflammation-in-the-cns
09/28/2018
Author(s): M.R. Pazos, V. Cinquina, A. Gómez, R. Layunta, M. Santos, J. Fernández Ruiz, José Martínez Orgado. CBD has been shown to have short-term neuroprotective effects in the immature brain, suggesting that it could be used as a neuroprotective agent for neonatal hypoxiaeischemia. View study
09/28/2018
Author(s): Ronen Durst, Haim Danenberg, Ruth Gallily, Raphael Mechoulam, Keren Meir, Etty Grad, Ronen Beeri, Thea Pugatsch, Elizabet Tarsish, and Chaim Lotan. CBD exhibits antioxidant and anti-inflammatory properties. These data highlight the anti-inflammatory and vascular stabilizing effects of CBD in endotoxic shock and suggest a potential beneficial effect of this natural cannabinoid. View study Krabbe disease (1)krabbe-disease Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. (2005). Author(s): Anke Witting, Lanfen Chen, Eiron Cudaback, Alex Straiker, Lisa Walter, Barry Rickman, Thomas Mo¨ ller, Celia Brosnan, and Nephi Stella. Through experimental methods, these studies suggest the potential of cannabinoids in the development of neuroprotective drugs for the treatment of multiple sclerosis. View study
09/28/2018
Author(s): Lili Yang a,n, Raphael Rozenfeld b, Defeng Wu b, Lakshmi A. Devi b, Zhenfeng Zhang c,n, Arthur Cederbaum. Cannabidiol prevents acute hepatic steatosis induced by alcohol in mice. The effective prevention of hepatic steatosis avoids the progressive damage caused by alcohol in the liver. View study
09/28/2018
Author(s): Michelle Roche and David P Finn. The CB2 receptor as a possible target for the treatment of neuroinflammatory and neurodegenerative disorders. View study
09/28/2018
Author(s): A.W. Zuardi2, J.A.S. Crippa2, J.E.C. Hallak2, F.A. Moreira and F.S. Guimarães. CBD could have anxiolytic (calming) and / or antipsychotic applications in patients. View study
09/28/2018
Author(s): C.D. Schubartc, I.E.C. Sommera, P. Fusar-Polib, L. de Wittea,R.S. Kahnc, M.P.M. Boksa,n. A review that concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of several currently available studies on the antipsychotic properties of CBD. View study
09/28/2018
Author(s): Leonora E Long, Daniel T Malone and David A Taylor. Cannabidiol acts as an agonist of the vanilloid channel 1 in the transient receptor potential family (TRPV1) and also to inhibit the hydrolysis and cellular uptake of the endogenous cannabinoid anandamide. Cannabidiol also has potential as an antipsychotic. View study
09/28/2018
Author(s): Lydie J Morel, Bruno Giros, and Vale´rie Dauge´,. THC acts as a homeostatic modifier that worsens the reward effects of morphine in naive animal models, but which would improve deficits in maternal models. This suggests the use of cannabis individuals subjected to an adverse postnatal environment. View study
09/28/2018
Author(s): Michelle Roche and David P Finn. The CB2 receptor as a possible target for the treatment of neuroinflammatory and neurodegenerative disorders. View study
09/28/2018
Author(s): A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira and F.S. Guimarães. CBD could have anxiolytic (calming) and / or antipsychotic applications in patients. View study
09/28/2018
Author(s): Yanhua Ren, John Whittard, Alejandro Higuera-Matas, Claudia V. Morris, and Yasmin L. Hurd. Using an animal model, this study examines the effects of CBD on the self-administration of heroin and concludes that it can be used effectively in patients with heroin addiction. View study
09/28/2018
Author(s): C.D. Schubartc, I.E.C. Sommera, P. Fusar-Polib, L. de Wittea,R.S. Kahnc, M.P.M. Boksa. A review that concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of several currently available studies on the antipsychotic properties of CBD. View study
09/28/2018
Author(s): Alline C. Campos, Manoela V. Fogac, Andreza B. Sonegoa, Francisco S. Guimarães. The neuroprotective properties of cannabidiol seem to depend on several cannabinoid-dependent and independent mechanisms. Preclinical evidence clearly indicate that cannabidiol represents a new opportunity for the treatment of several brain disorders (such as neurodegenerative and neuropsychiatric) where neuronal loss or damage plays a significant role. View study
09/28/2018
Author(s): Leonora E Long, Daniel T Malone and David A Taylor. Cannabidiol acts as an agonist of the vanilloid channel 1 in the transient receptor potential family (TRPV1) and also to inhibit the hydrolysis and cellular uptake of the endogenous cannabinoid anandamide. Cannabidiol also has potential as an antipsychotic. View study
09/28/2018
Author(s): Amanda Reiman. This study was conducted based on data collected in an anonymous survey to examine the use of alcohol and drugs, and the occurrence of substitution among medicinal cannabis patients. It was found that the reasons for the substitution were: fewer adverse side effects (65%), better management of symptoms (57%) and less potential for abstinence (34%) with cannabis. As a result of this study it was found that medicinal cannabis patients have been participating in the substitution using cannabis as an alternative to alcohol, prescriptions and illicit drugs. View study
09/28/2018
Author(s): Ana Juknat, Ewa Kozela, Nathali Kaushansky, Raphael Mechoulam and Zvi Vogel. This study demonstrates that dimethylheptyl-cannabidiol (DMH-CBD) has anti-inflammatory and antiproliferative properties similar to cannabidiol (CBD). DMH-CBD acts by negatively regulating the expression of inflammatory cytokines and protecting microglial cells by inducing an adaptive cellular response against inflammatory stimuli and oxidative lesions. View study
09/28/2018
Author(s): Institute for Quality and Efficiency in Health Care. Benefits of Cannabis sativa extract in the treatment of patients with spasticity due to multiple sclerosis. View study
09/28/2018
Author(s): L. Lorente Fernández b,∗, E. Monte Boquet b, F. Pérez-Miralles a, I. Gil Gómez b, M. Escutia Roig a, I. Boscá Blascoa, J.L. Poveda Andrés b, B. Casanova-Estrucha. THC and CBD seem to be an excellent alternative for multiple sclerosis treatments, since it improves refractory spasticity and has an acceptable toxicity profile. View study